Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095437
Filing Date
2024-08-12
Accepted
2024-08-12 16:12:29
Documents
76
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q eras-20240630.htm   iXBRL 10-Q 2018601
2 EX-10.1 eras-ex10_1.htm EX-10.1 729329
3 EX-10.2 eras-ex10_2.htm EX-10.2 495617
4 EX-31.1 eras-ex31_1.htm EX-31.1 14596
5 EX-31.2 eras-ex31_2.htm EX-31.2 14629
6 EX-32.1 eras-ex32_1.htm EX-32.1 7850
7 EX-32.2 eras-ex32_2.htm EX-32.2 8119
8 GRAPHIC img199613521_0.jpg GRAPHIC 219502
  Complete submission text file 0000950170-24-095437.txt   11191933

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eras-20240630.xsd EX-101.SCH 1246637
79 EXTRACTED XBRL INSTANCE DOCUMENT eras-20240630_htm.xml XML 1865844
Mailing Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121
Business Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121 (858) 465-6511
Erasca, Inc. (Filer) CIK: 0001761918 (see all company filings)

EIN.: 831217027 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40602 | Film No.: 241196898
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)